Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~6 days
Time for 50 % to be eliminated
Steady State
~25.9 days
≈ 4.3 half-lives
Accumulation
×1.80
Cmax at steady state ÷ Cmax first dose
Gone After
~42 days
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 109.2 | 59.1 |
| 209.3 | 118.5 |
| 318.5 | 70 |
| 418.6 | 110.5 |
| 518.7 | 161.4 |
| 627.9 | 95.4 |
| 728 | 135.3 |
| 837.2 | 80 |
| 937.3 | 112 |
| 1037.4 | 156 |
| 1146.6 | 92.2 |
| 1246.7 | 128.1 |
| 1355.9 | 75.7 |
| 1465.1 | 44.8 |
| 1574.3 | 26.5 |
| 1683.5 | 15.6 |
| 1792.7 | 9.3 |
| 1901.9 | 5.5 |
| 2011.1 | 3.2 |
| 2120.3 | 1.9 |
Source: Eli Lilly SURMOUNT clinical trial data. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Retatrutide: ~6 days.
Retatrutide has a reported half-life of about 6 days. Under a weekly dosing schedule, steady state is reached at roughly 4.3 half-lives — about 26 days — and subsequent doses accumulate by a factor of about 1.8 over a single dose.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 42 days — seven half-lives.
Retatrutide is a triple GLP-1/GIP/GCG receptor agonist studied at weekly doses of 0.5 to 12 mg. The long half-life is what makes weekly dosing feasible and steady-state accumulation predictable.